FDA Grants Orphan Drug Designation to Neurogene’s Gene Therapy for the Treatment of CLN5 Batten Disease

CLN5 is a devastating neurodegenerative disease with no FDA approved treatment options, said Rachel McMinn, Ph.D., Neurogenes Founder and Chief Executive Officer.